电力设备及新能源 2025 年 4 月 21 日 行业周报 光伏主材价格回落，华能优先风电项目开发 强于大市（维持） 行情走势图 -20% -10% 0% 10% 20% 30% 2024/04/17 2024/09/17 2025/02/17 沪深300指数 电力设备及新能源 证券分析师 平安观点： 本周（2025.4.14-2025.4.18） 新 能 源 细分 板 块 行情 回 顾 。风电指数 （866044.WI）上涨 0.47%，跑输沪深 300 指数 0.12 个百分点。截至本 周，风电板块 PE_TTM 估值约 18.89 倍。本周 申万 光伏 设 备 指 数 （801735.SI）下跌 1.92%，其中，申万光伏电池组件指数下跌 1.19%， 申万光伏加工设备指数下跌 2.13%，申万光伏辅材指数下跌 1.8%，当前 光伏板块市盈率约 29.37 倍。本周储能指数（884790.WI）下跌 0.77%， 当前储能板块整体市盈率为 22.93 倍；氢能指数（8841063.WI）下跌 0.27%，当前氢能板块整体市盈率为 28.17 倍。 本周重点话题 行 业 周 报 证 券 研 究 报 告 行 ...

医药 2025 年 04 月 21 日 千红制药(002550.SZ) 24年利润端实现快速增长，创新管线有望贡献弹性 推荐（维持） | 叶寅 | 投资咨询资格编号 | | --- | --- | | | S1060514100001 | | | BOT335 | | | YEYIN757@pingan.com.cn | | 研究助理 | | | 臧文清 | 一般证券从业资格编号 | | | S1060123050058 | | | ZANGWENQING222@pingan.com.cn | 事项： 2025 年 4 月 19 号，千红制药发布 2024 年年报和 2025 年一季报，24 年共实 现收入 15.26 亿元（-15.88%），归母净利润 3.56 亿元（+95.77%），扣非后归 母净利润 2.69 亿（+87.48%），利润端实现快速增长。利润分配预案：每 10 股 派发现金红利 1.2 元（含税）。25Q1 公司实现收入 4.51 亿元（-2.22%），归母 净利润 1.61 亿元（+54.62%），主要系收回部分建元信托前期逾期款项，扣非 后归母净利润 1.07 亿（+4.84%）。 ...

Investment Rating - The report maintains a "Recommended" rating for the company, with a current stock price of 84.77 yuan [1]. Core Views - The company has shown a significant improvement in the gross margin of its reducers, demonstrating scalable precision manufacturing capabilities [1][7]. - In 2024, the company achieved a revenue of 976 million yuan, a year-on-year decrease of 10.10%, while the net profit attributable to shareholders was 72.55 million yuan, a decrease of 0.82% year-on-year [4][7]. - The company has a strong market position in small and micro gear motors and has made technological breakthroughs in precision reducers, competing effectively against foreign companies [8]. Financial Performance Summary - **Revenue and Profitability**: The company’s revenue is projected to recover to 1,084 million yuan in 2025, with a net profit of 89 million yuan, reflecting a year-on-year growth of 23.2% [6][10]. - **Gross Margin**: The gross margin for 2024 is reported at 25.9%, an increase of 3.02 percentage points year-on-year, indicating improved cost management [7][10]. - **Earnings Per Share (EPS)**: The EPS is expected to grow from 0.48 yuan in 2024 to 0.59 yuan in 2025, with further increases projected in subsequent years [6][10]. Product and Market Position - The company focuses on key components in the mechanical transmission and control application fields, with a product structure that includes reducers, gear motors, and intelligent actuators [8]. - The main products, including gear motors and precision reducers, have shown sales growth, with the precision reducer's gross margin increasing by 10.57 percentage points year-on-year [7][8]. - The company is actively expanding into humanoid robot components, positioning itself well in the growing market for robotics [8]. Financial Ratios and Projections - **Return on Equity (ROE)**: The ROE is projected to improve from 6.2% in 2024 to 8.7% by 2027, indicating enhanced profitability [10]. - **Debt Ratios**: The asset-liability ratio is expected to decrease from 28.3% in 2024 to 24.7% in 2027, reflecting a stronger balance sheet [10]. - **Cash Flow**: Operating cash flow is projected to be 131 million yuan in 2025, indicating healthy cash generation capabilities [11].

其 他 报 告 2025年04月21日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3277 | -0.11 | 1.19 | | 深证成份指数 | 9782 | 0.23 | -0.54 | | 沪深300指数 | 3773 | 0.01 | 0.59 | | 创业板指数 | 1914 | 0.27 | -0.64 | | 上证国债指数 | 224 | -0.01 | 0.02 | | 上证基金指数 | 6727 | -0.03 | 0.32 | | | | 资料来源:同花顺iFinD | | 今日重点推荐： 【平安证券】行业深度报告*石油石化*生物柴油行业深度系列 （一）：出口困境尾声，内需空间广阔*强于大市20250420 研究分析师 : 陈潇榕 投资咨询资格编号 : S1060523110001 研究分析师 : 马书蕾 投资咨询资格编号 : S1060524070002 核心观点 : 生物柴油：政策刺激需求释放，中国出口利空面渐出尽。在多国政策 推动下，全球生物柴油消费量呈现 ...

平安观点： 基 金 报 告 基 金 周 报 2025 年 04 月 20 日 基金周报 黄金股板块表现优异，首批科创综指增强策略 ETF 上报 证券分析师 | 郭子睿 | | 投资咨询资格编号 | | --- | --- | --- | | | | S1060520070003 | | | | GUOZIRUI807@pingan.com.cn | | 陈 | 瑶 | 投资咨询资格编号 | | | | S1060524120003 | | | | CHENYAO370@pingan.com.cn | | 研究助理 | | | 证 券 研 究 报 告 任书康 一般证券从业资格编号 S1060123050035 RENSHUKANG722@pingan.com.cn 胡心怡 一般证券从业资格编号 S1060124030069 HUXINYI184@pingan.com.cn 高 越 一般证券从业资格编号 S1060124070014 GAOYUE384@pingan.com.cn 市场回顾：上周 A 股市场上行。上证指数周内上涨 1.19%，收于 3,276.73， 最高 3,285.92；深证成指周内下跌 0. ...

证券研究报告 OpenAI o3、豆包新品首发, 央行等六部门发文规范金融业数据跨境流动 计算机行业 强于大市（维持） 平安证券研究所计算机团队 分析师：闫磊S1060517070006(证券投资咨询)YANLEI511@pingan.com.cn 黄韦涵S1060523070003(证券投资咨询)HUANGWEIHAN235@pingan.com.cn 研究助理：王佳一S1060123070023（一般证券从业资格）WANGJIAYI446@pingan.com.cn 2025年4月20日 请务必阅读正文后免责条款 核心摘要 行业要闻及简评：1）OpenAI o3、豆包新品首发，关注原生Agent与多模态推理。4月17日，OpenAI公司发布o系列模型中的最新款o3和 o4-mini，火山引擎发布豆包1.5·深度思考模型等新品。o3和o4-mini被称为是OpenAI迄今为止发布的最智能的模型，首次实现在思维 链中用图像来思考，结合高级推理与 Web 搜索、图像处理等工具（自动缩放、裁剪、翻转或增强图像），以及推理模型首次可以代理 使用和组合ChatGPT中的各个工具，包括搜索网络、使用Python分析上传 ...

前瞻性产业研究 2025 年 4 月 20 日 证券分析师 养老金融双周报（2025.04.14-2025.04.20） 美国地方法院阻止 DOGE 调查社保欺诈案 | 陈骁 | 投资咨询资格编号 | | --- | --- | | | S1060516070001 | | | chenxiao397@pingan.com.cn | 郝博韬 投资咨询资格编号 S1060521110001 haobotao973@pingan.com.cn 石艺 投资咨询资格编号 S1060524070003 SHIYI262@pingan.com.cn 平安观点： 本期重点：美国地方法院禁止 DOGE 调查社保欺诈案 第一，美国联邦法官拟禁止政府效率部门访问社会保障数据。4 月 15日， 美国总统特朗普签署了一份备忘录，要求埃隆·马斯克的"政府效率部" （DOGE）打击社会保障项目中的欺诈行为。核心是限制无证移民领取社 会保障退休福利。4 月 17 日，美国马里兰州联邦法院发布初步禁令，禁止 DOGE 访问包含个人身份信息在内的任何美国社会保障局（SSA）系统。 根据禁令，DOGE 及其团队成员和附属机构需要交出并删除其掌控 ...

Investment Rating - Industry investment rating: Real Estate Stronger than the Market (maintained) [1] Core Insights - Policy expectations are rising, enhancing the risk-reward ratio for the sector. The Prime Minister emphasized the need for new support measures during a recent survey in Beijing, coinciding with the upcoming Politburo meeting at the end of April. The report suggests that the short-term investment risk-reward ratio for the sector is improving due to potential policy enhancements aimed at boosting domestic demand and supporting the real estate market [2][3] - The report estimates that the potential demand for residential properties in China from 2025 to 2030 is around 876 million square meters, with 2024 sales expected to be 810 million square meters, indicating a significant gap. The promotion of "good houses" is expected to accelerate the release of improvement and replacement demand [2] - Short-term policy and fundamental factors are expected to resonate positively, while the long-term product iteration presents new opportunities. Recommended stocks include companies with strong product capabilities and optimized inventory structures, such as China Resources Land, China Overseas Development, and Poly Developments [2] Summary by Sections Policy Environment Monitoring - The Prime Minister highlighted the significant development space in China's real estate market. Recent new policies in cities like Wuxi, Qingdao, and Suzhou aim to stimulate housing demand and support families with multiple children [6] Market Operation Monitoring - Transaction volume remains stable, with new home sales in 50 key cities at 14,000 units, a slight decrease of 0.1% week-on-week. The average daily sales for new homes in April show a year-on-year decline of 22.2% [9][12] Capital Market Monitoring - The real estate sector saw a 3.4% increase in stock prices, outperforming the CSI 300 index, which rose by 0.59%. The current price-to-earnings ratio (TTM) for the real estate sector is 35.72, significantly higher than the CSI 300's 12.26, indicating a high valuation relative to historical levels [23][29]

Investment Rating - The industry investment rating is "Outperform the Market" [1][50]. Core Insights - Eli Lilly's first oral small molecule GLP-1 drug, Orforglipron, has successfully completed Phase 3 clinical trials, which is expected to change the landscape of weight loss medications [3][4]. - The ACHIEVE-1 trial showed that Orforglipron significantly reduced HbA1c levels by 1.3% to 1.6% from a baseline of 8.0% after 40 weeks, with over 65% of patients achieving HbA1c levels ≤6.5% [3][4]. - Patients receiving the highest dose of Orforglipron lost an average of 7.3 kg, indicating potential for further weight loss [4]. - Eli Lilly plans to submit a global application for Orforglipron for weight management by the end of this year and for type 2 diabetes treatment in 2026 [4][5]. Summary by Sections Industry Overview - The successful Phase 3 trial of Orforglipron positions it as a potential second oral GLP-1 drug in the U.S., following Novo Nordisk's Rybelsus [5]. Investment Strategy - Focus on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [7]. - Recommended companies include innovative drug developers and those with strong overseas market potential [7]. Key Companies to Watch - **Nocera Health**: Expected to achieve over 1 billion yuan in revenue from its core product, with a projected 49% year-on-year growth [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [11]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [13]. - **Aier Eye Hospital**: Benefiting from increasing demand in ophthalmology and ongoing overseas expansion [22]. Market Performance - The pharmaceutical sector saw a decline of 0.36% last week, while the broader market index rose by 0.59% [25][36].

Investment Rating - The industry investment rating is "Outperform the Market" which indicates an expected performance of the industry index to exceed the market performance by more than 5% over the next six months [16]. Core Viewpoints - The cultural and entertainment industry is expected to experience diversified growth due to favorable national policies, leading to a continued recovery in the media sector. The report suggests focusing on companies with strong earnings certainty, high dividend yields, and stable payout ratios [3]. - The gaming and IP sector is anticipated to enter a new product cycle supported by government encouragement of cultural consumption. Companies in this sector are expected to benefit from cost reduction and efficiency improvements through technologies like AIGC [3]. - The film and cinema industry is gradually recovering with an increase in the number of films, supported by ongoing policy backing and a favorable valuation for leading companies [3]. - The advertising and marketing sector is recovering at a slower pace, with a focus on companies with strong client structures and channel resources, particularly those with improving profit margins [4]. - In the digital media and publishing sectors, leading companies are expected to maintain stable market shares, with growth opportunities in new business expansions [4]. Summary by Sections Gaming and IP - The gaming sector is expected to benefit from new product cycles and technological advancements, with a focus on leading companies such as 37 Interactive Entertainment, Perfect World, and Gigabit Network [3]. Film and Cinema - The film industry is seeing a recovery in supply, with an increase in film quantity and improved performance from leading companies like Wanda Film and Light Media [3]. Advertising and Marketing - The advertising sector is experiencing a slow recovery, with a focus on leading companies like Focus Media and BlueFocus Communication Group, which have strong market positions and improving profit margins [4]. Digital Media and Publishing - In digital media, companies like Mango Super Media are expected to maintain strong positions, while the publishing sector shows positive growth in educational and children's book sales [4][12].